# A brain scan can leave a morning unexplained

A brain finding

A change in brain activity still leaves a question about daily life.

A sharper mind and a better night are easy things to want. The harder part is finding research that measures them. I read Semax and DSIP studies with the following day in mind: did anyone test something a person would actually notice?

## Semax gives a signal something to explain

[Semax is a man-made peptide based on part of a natural stress hormone](https://www.fda.gov/media/193348/download). That explains its design. It doesn’t tell us whether it improves someone’s memory.

A [small study in healthy volunteers found a change in resting brain activity](https://pubmed.ncbi.nlm.nih.gov/30225715/). It used functional MRI, a brain scan that tracks blood flow. The finding didn’t establish better memory or focus in everyday life.

FDA’s [review found limited clinical evidence and incomplete safety reporting](https://www.fda.gov/media/193348/download). Most of the work came from a few Russian research groups. The language isn’t the problem; the missing large, independent trials leave the everyday claim unsettled.

## DSIP carries a sleep claim in its name

DSIP means delta sleep-inducing peptide; emideltide is another name for it. Delta refers to the slow brain waves of deep sleep. It’s quite a promise for a name to carry.

An older [study in people with long-running insomnia](https://pubmed.ncbi.nlm.nih.gov/1299794/) found some sleep measures improved against placebo, a comparison without the active substance. Neither participants nor assessors knew who got which. The authors called the effects modest and doubted that short-term treatment alone offered much practical benefit.

A later [review found the sleep link weakly established](https://pubmed.ncbi.nlm.nih.gov/16539679/). Even its specific receptor, the place where it would deliver its message, remained unidentified. The name gets ahead of the answer.

![An adult lies awake on one side in a quiet bedroom before dawn, looking toward a closed curtain.](/nexus-between-e0d651e57312/morning-at-the-window.webp)

Being awake when you meant to sleep is the problem in the older DSIP trial. This is an ordinary bedroom illustration, not a participant or a treatment result.

## Two questions can share a day

Wanting better focus and better sleep doesn’t create evidence that Semax and DSIP work together. They share a page because readers bring related questions, not because a combination has been established.

For focus, I want a study of a meaningful task in people like the reader. For sleep, I want to know about the night and the next day. A scan change can be interesting while leaving both questions open.

## Uncertainty includes unwanted effects

Semax is not FDA-approved. FDA found [too little information to describe its safety in people](https://www.fda.gov/media/193348/download). It also raised a bleeding concern from rat findings. That’s a warning to investigate, not proof of a measured human effect.

DSIP is not FDA-approved either. Its [basic biology remains unresolved](https://pubmed.ncbi.nlm.nih.gov/16539679/), and long-term human safety and interactions are unknown. An old, small study can’t fill that gap. Persistent sleep or concentration problems belong in a conversation with a licensed U.S. clinician who can assess the problem itself.